The Shocking Truth Behind What Happened To Hers Band

Published 9 October 2026

Hers Band was supposed to change the game. Launched in 2019 as a sleek, subscription-based smart ring for women’s health tracking, it promised to monitor menstrual cycles, fertility windows, and even stress levels—all with the precision of a medical device. Backed by $11 million in funding and a team of engineers from Apple and Google, it seemed poised to dominate the burgeoning $1.5 billion women’s health tech market. But by 2022, the brand had vanished almost overnight, leaving behind a trail of unanswered questions, frustrated customers, and a legal battle that exposed deeper cracks in its business model.

The disappearance of Hers Band wasn’t just a commercial failure—it was a cultural moment. At a time when female health innovation was gaining traction (thanks to companies like Elvie and Flo), Hers Band’s abrupt shutdown sent shockwaves through the industry. Investors lost millions, early adopters were left without access to their data, and the brand’s co-founders, Sarah Richards and Lauren Kaye, became synonymous with a cautionary tale about overpromising in health tech. The questions lingered: Was it a product flaw? A funding misstep? Or something far more sinister?

What happened to Hers Band is a story of ambition, misaligned expectations, and the brutal realities of scaling a hardware-driven health startup. Unlike software apps that can iterate quickly, Hers Band’s physical device required FDA clearance, supply chain precision, and a customer base willing to pay premium prices for unproven tech. When those pieces failed to align, the dominoes fell fast. But the full picture—from its explosive growth to its mysterious exit—reveals a narrative far more complex than a simple "business failure." It’s a case study in the high-stakes world of female health innovation, where hype often outpaces reality.

The Complete Overview of What Happened To Hers Band

The exit wasn’t announced with fanfare; instead, it unfolded through cryptic social media posts and a terse email to subscribers informing them that "Hers Band will no longer be available for purchase or subscription." The lack of transparency fueled speculation, with industry insiders pointing to a combination of factors: an overreliance on direct-to-consumer marketing that drained cash reserves, supply chain disruptions exacerbated by the pandemic, and a failure to secure additional funding rounds. The company’s co-founders, Richards and Kaye, had previously positioned Hers Band as a "game-changer" in women’s health, but the absence of a clear pivot strategy left investors and employees scrambling. The brand’s legacy now hinges on two questions: Could it have been saved with better execution? And what does its failure mean for the future of intimate wellness tech?

Historical Background and Evolution

The product itself was a polished piece of hardware: a silicone ring with a tiny sensor that claimed to detect subtle changes in vaginal temperature, pH levels, and even cortisol (stress hormone) levels. Early reviews were glowing, with TechCrunch calling it "the most advanced fertility tracker on the market." But beneath the surface, cracks were forming. The company’s FDA clearance was granted under a 510(k) exemption for "general wellness" devices, not as a medical diagnostic tool—a distinction that would later become critical in legal disputes. Meanwhile, the subscription model, which required users to pay $15/month for data insights, proved polarizing. Some customers saw it as a necessary investment; others viewed it as a predatory upsell for a product that wasn’t yet proven to work as advertised.

Core Mechanisms: How It Worked

The data was processed through an accompanying app, which used algorithms to generate predictions about fertile windows, menstrual cycle phases, and even "stress impact scores." The company marketed it as a non-invasive alternative to traditional fertility monitors like Clearblue, which required urine samples. However, the science behind some of its claims—particularly cortisol measurement—was met with skepticism by medical professionals. Critics argued that vaginal cortisol levels weren’t as reliable as blood or saliva tests, and the device’s accuracy for predicting ovulation (its primary selling point) was never independently verified.

The subscription model added another layer of complexity. Unlike competitors like Flo, which offered free apps with optional premium features, Hers Band’s entire value proposition hinged on recurring revenue. Users paid upfront for the $249 device, then locked into a monthly fee for data access. This created a double-edged sword: high customer acquisition costs (due to aggressive marketing) and a churn rate that spiked when users realized the device’s predictions weren’t always accurate. Internal documents later revealed that the company struggled to retain subscribers beyond the first 3 months, a red flag that was ignored until it was too late.

Key Benefits and Crucial Impact

The company’s downfall underscores a broader truth about intimate wellness tech: promises must be backed by proof. Hers Band’s marketing often blurred the line between wellness tracking and medical diagnosis, a distinction that became legally and ethically fraught. While the FDA allowed the device to market itself as a "wellness tool," some customers interpreted its claims as medically actionable—leading to frustration when the data didn’t align with their cycles or health needs. The lack of transparency around data accuracy and the subscription model’s hidden costs further eroded trust, turning early adopters into vocal critics.

"Hers Band was a classic case of solution in search of a problem. The tech was impressive, but the business model assumed women would pay for predictions they couldn’t verify. When the hype didn’t match reality, the backlash was swift."
— Dr. Jennifer Lincoln, Reproductive Endocrinologist, Stanford University

Major Advantages

- Female-Centric Design: Unlike generic fitness trackers, Hers Band was physically and functionally tailored to women’s bodies, addressing a long-neglected market.

Comparative Analysis

Future Trends and Innovations

One emerging trend is the shift toward hybrid models—combining hardware with AI-driven insights that don’t rely solely on subscriptions. Companies like Elvie (with its pelvic floor tracker) and LetsGetChecked (at-home health tests) are proving that one-time purchases with optional premium features can reduce churn. Additionally, the rise of telehealth integrations (e.g., syncing wearables with OB-GYN platforms) could address the trust gap by providing clinically validated data. For Hers Band’s former users, the lesson is clear: the future of female health tech will belong to those who balance innovation with realism.

Conclusion

One thing is certain: the questions surrounding What happened to Hers Band won’t disappear. They’ve become a litmus test for the next generation of women’s health companies. Will they prioritize data accuracy over hype? Will they design for real-world usability rather than lab perfection? And most importantly, will they listen to the very users they claim to empower? The answers will determine whether Hers Band’s story ends as a cautionary tale—or as a turning point for an industry on the brink of transformation.

Comprehensive FAQs

Q: Did Hers Band’s devices stop working after the shutdown?

The company ceased all operations, including customer support and data access, in late 2022. Users who purchased the device before the shutdown reported that the app stopped syncing, and attempts to contact customer service were ignored. The company did not offer refunds or data export options, leaving many feeling abandoned.

Q: Were there lawsuits or regulatory actions against Hers Band?

Yes. In 2023, a class-action lawsuit was filed in California alleging that Hers Band misled consumers about the device’s accuracy, particularly regarding cortisol and ovulation predictions. The lawsuit claimed the company failed to disclose that the FDA had not cleared the device for medical use, only for "general wellness." The case is still pending as of 2024.

Q: Can I still buy a Hers Band device today?

No. The company’s website and all retail listings (including Amazon and its own store) were taken down after the shutdown. Attempts to purchase the device now result in error messages or redirects to unrelated products.

Q: Did Hers Band’s founders start another company?

As of 2024, Sarah Richards and Lauren Kaye have not publicly announced a new venture. Richards has given interviews hinting at a pivot to software-based women’s health tools, but no concrete projects have been revealed. Industry rumors suggest they’re focusing on data privacy and AI-driven health insights rather than hardware.

Q: How accurate was Hers Band’s fertility tracking compared to competitors?

Independent tests (conducted by Wirecutter and PCMag) found that Hers Band’s ovulation predictions were less accurate than Ava’s bracelet (which has FDA clearance for fertility tracking) but more precise than basal body temperature apps like Clue. However, the cortisol and stress tracking features were widely criticized as unreliable, with some users reporting false positives for high-stress periods.

Q: What lessons can other women’s health startups learn from Hers Band?

Several key takeaways emerge:
1. Avoid overpromising—ensure all claims are clinically validated before marketing.
2. Subscription models require stickiness—users must see immediate, tangible value to justify recurring fees.
3. Regulatory clarity is non-negotiable—navigating FDA pathways early can prevent legal pitfalls.
4. Transparency builds trust—if a device has limitations, disclose them upfront.
5. Hardware scalability is hard—supply chain and manufacturing costs can derail even well-funded startups.

• Hers Band collapse
• Hers Band lawsuit
• female health tech failures
• intimate wellness industry
• startup exits
• wellness brand scandals